Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
metastatic non-small cell lung cancer after a pre-planned futility analysis, while reporting no new safety issues and confirming that zimberelimab plus chemotherapy showed overall survival in line with pembrolizumab plus chemotherapy. On the same day, Arcus disclosed that Gilead will allow its broader option rights on several early-stage Arcus programs to lapse in July 2026, narrowing the collaboration's future scope while leaving Arcus with full rights to casdatifan outside territories licensed to Taiho. We'll now examine how discontinuing STAR-121 and EDGE-Lung may reshape Arcus Biosciences' investment narrative centered on casdatifan and oncology development. Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Arcus Biosciences Investment Narrative Recap To own Arcus Biosciences today, you need to believe its oncology pipeline, now centered on cas
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now [Seeking Alpha]Seeking Alpha
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesBusiness Wire
- Arcus Biosciences (RCUS) was given a new $47.00 price target by Leerink Partners.MarketBeat
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
RCUS
Earnings
- 2/25/26 - Beat
RCUS
Sec Filings
- 4/23/26 - Form 144
- 4/21/26 - Form ARS
- 4/21/26 - Form DEFA14A
- RCUS's page on the SEC website